Topoisomerase Inhibitors

An overview of topoisomerase inhibitors, their mechanisms, and clinical applications.

Topoisomerase inhibitors are a class of drugs that interfere with the action of topoisomerase enzymes, which are essential for DNA replication, transcription, and DNA repair. These inhibitors are primarily used in the treatment of cancer, as they can prevent the proliferation of rapidly dividing tumor cells.

Mechanism of Action

Topoisomerases are enzymes that manage the topology of DNA molecules. They are crucial for relieving the torsional strain that occurs during DNA replication and transcription. There are two main types of topoisomerases:

• Topoisomerase I cuts one strand of the DNA helix, allowing it to unwind and relieve tension, and then reseals the strand.
• Topoisomerase II cuts both strands of the DNA helix, allowing the passage of another segment of DNA through the break before resealing it.

Topoisomerase inhibitors work by stabilizing the transient break made by the enzyme, preventing the re-ligation of the DNA strands. This leads to the accumulation of DNA breaks, ultimately triggering cell death.

Types of Topoisomerase Inhibitors

Topoisomerase inhibitors are classified based on the type of topoisomerase they target:

Topoisomerase I Inhibitors

These inhibitors bind to the topoisomerase I-DNA complex, preventing the re-ligation of the single-strand break. Examples include:

• Irinotecan - Used primarily in the treatment of colorectal cancer.
• Topotecan - Used in the treatment of ovarian cancer and small cell lung cancer.

Topoisomerase II Inhibitors

These inhibitors stabilize the topoisomerase II-DNA complex, preventing the re-ligation of the double-strand break. Examples include:

• Etoposide - Used in the treatment of testicular cancer, lung cancer, and lymphoma.
• Doxorubicin - A widely used anthracycline antibiotic effective against a variety of cancers, including breast cancer and leukemia.

Clinical Applications

Topoisomerase inhibitors are primarily used in oncology. Their ability to induce DNA damage makes them effective against rapidly dividing cancer cells. However, their use is associated with significant side effects, including myelosuppression, gastrointestinal toxicity, and the potential for secondary malignancies due to their genotoxic effects.

Resistance Mechanisms

Cancer cells can develop resistance to topoisomerase inhibitors through various mechanisms, such as:

• Overexpression of topoisomerase enzymes, which can dilute the effect of the inhibitor.
• Mutations in topoisomerase genes, reducing drug binding affinity.
• Efflux pumps, which actively transport the drug out of the cell, reducing intracellular concentrations.

Research and Development

Ongoing research aims to develop new topoisomerase inhibitors with improved efficacy and reduced toxicity. Novel agents are being investigated for their ability to overcome resistance mechanisms and target specific cancer types more effectively.

Also see

• DNA replication
• Cancer chemotherapy
• Enzyme inhibitors
• Pharmacology